Evidence map›Paper›PMID 40944618›Full record

ArticleNephrology (Carlton, Vic.)2025

Novel Pathogenic Genotype in SLC12A3 Associated to Gitelman Syndrome: A Case Report.

Patricia Tomás-Simó, Antonio Sierra-Rivera, Ana Checa-Ros, Raquel Rodríguez-López, Antonio Galán-Serrano, Luis D'Marco

Abstract readCase Reports
In one paragraph

Article in Nephrology (Carlton, Vic.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Patricia Tomás-SimóNephrology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Spain.
Antonio Sierra-RiveraGenetics Section, Clinical Analysis Service, Consorcio Hospital General Universitario de Valencia, Valencia, Spain.ORCID https://orcid.org/0000-0001-7824-7239
Ana Checa-RosCardiorenal and Metabolic Diseases Research Group, Department of Medicine and Surgery, Faculty of Health Sciences, Cardenal Herrera-CEU University, CEU Universities, Valencia, Spain.ORCID https://orcid.org/0000-0001-8958-6711
Raquel Rodríguez-LópezGenetics Section, Clinical Analysis Service, Consorcio Hospital General Universitario de Valencia, Valencia, Spain.ORCID https://orcid.org/0000-0001-5865-5382
Antonio Galán-SerranoNephrology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Spain.
Luis D'MarcoCardiorenal and Metabolic Diseases Research Group, Department of Medicine and Surgery, Faculty of Health Sciences, Cardenal Herrera-CEU University, CEU Universities, Valencia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gitelman syndrome (GS) is considered one of the most common hereditary renal tubular disorders, characterised by hypokalemia, hypomagnesemia, hypocalciuria, and metabolic alkalosis. The primary cause of this disorder resides in the SLC12A3 gene, which encodes the NaCl cotransporter in the distal convoluted tubule, and for which more than 500 mutations associated with GS have been described. We present the case of a 51-year-old female referred for evaluation of recurrent hypokalemia and hypomagnesemia, with no clinical symptoms. The blood test also revealed hypocalciuria and metabolic alkalosis. Oral supplementation with potassium and magnesium was prescribed. A next-generation sequencing (NGS) test was performed on her and her child (no other relatives alive), who was also asymptomatic with no obvious electrolytic abnormalities. Two mutations confirmed as pathogenic were found in the SLC12A3 gene (NM_000339.3) of the mother, c.704C>G and c.704C>T, as well as a new heterozygous variant in trans not reported before, c.704C>A p.(Thr235Lys), and identified as a variant of uncertain significance (VUS). This new VUS (c.704C>A p) was also present in the child, increasing evidence of its potential pathogenicity. The new SLC12A3 gene variant could represent a pathogenic mutation associated with GS. The use of NGS-based panel is recommended to cover the large genotypic variability associated with this disease, in an attempt to identify novel SLC12A3 gene variants of potential pathogenicity.

Indexed as

Gitelman SyndromeMutationSolute Carrier Family 12, Member 3DNA Mutational AnalysisFemaleGenetic Predisposition to DiseaseGenotypeHumansHypokalemiaMiddle AgedPhenotypeSLC12A3 protein, humanSolute Carrier Family 12, Member 3ACMG criteriaGitelman syndromehypokalemianext‐generation sequencingpathogenicitySLC12A3

Identifiers

PMID40944618
PMCPMC12433184

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.